The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
This study examines the effect of nicotinic acid (1 g t.d.s.) on serum Lp(a) concentration in a group of patients with type II hyperlipidaemia selected on the basis of a plasma Lp(a) concentration greater than 30 mg/dl. Reductions in total cholesterol, triglyceride, LDL-cholesterol and Lp(a) were 16.3%, 25.5%, 23.7% and 36.4%, respectively, with an increase in HDL cholesterol of 37.3%. The reduction in Lp(a) concentration did not correlate with any other lipoprotein changes. In order to establish the mechanism of the fall in Lp(a) concentration, in vivo turnover of autologous Lp(a) was studied in three subjects before and whilst taking nicotinic acid. The fractional catabolic rate in Lp(a) was unaltered in the subjects on therapy, indicating that nicotinic acid did not increase catabolism of Lp(a) but decreased the synthetic rate. Since nicotinic acid was poorly tolerated we examined the effect of acipimox, an analogue of nicotinic acid on lipoproteins using a placebo controlled double-blind crossover design in a group of hyperlipidaemic patients again selected with plasma Lp(a) concentration greater than 30 mg/dl. Acipimox was better tolerated than nicotinic acid but the percentage changes in lipoprotein concentrations were smaller.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by ≏ 30%. 115-117”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [117]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
BMDP Statistical Software 1981.
Bubolz, T. A., & Dixon, W. J. (1984) · Journal of the American Statistical Association · doi:10.2307/2288308 · Cited by 5,221
Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions
BURSTEIN, M., SCHOLNICK, H. R., & MORFIN, R. (1970) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42943-8 · Cited by 2,491
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Nonparametric Statistics for the Behavioral Sciences
(2010) · Encyclopedia of Research Design · doi:10.4135/9781412961288.n273 · Cited by 1,414
Utermann, G., Menzel, H. J., Kraft, H. G., Duba, H. C., Kemmler, H. G., & Seitz, C. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113093 · Cited by 881
The Theory of Tracer Experiments with 131I-Labelled Plasma Proteins
Matthews, C. M. E. (1957) · Physics in Medicine & Biology · doi:10.1088/0031-9155/2/1/305 · Cited by 829
Lipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Armstrong, V. W., Cremer, P., Eberle, E., Manke, A., Schulze, F., Wieland, H., Kreuzer, H., & Seidel, D. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90099-7 · Cited by 626
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Bergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 282
Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes
Cantó, C., Sauve, A. A., & Bai, P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.004 · Cited by 246
“However, acipomox has been reported to exhibit smaller effects than NA in lipid modulation (Seed et al., 1993), and acipomox did not cause statistically significant increase of HDL in one study (Seed et al., 1993).”
Background
Metadata
- Authors
- Seed, M., O'Connor, B., Perombelon, N., O'Donnell, M., Reaveley, D., & Knight, B. L.
- Affiliations
- Charing Cross Hospital (GB)
- Hammersmith Hospital (GB)
- Corresponding author
- Seed, Mary
- ORCID
- Knight, Brian L.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 1993-06
- Volume
- 101
- Issue
- 1
- Pages
- 61-68
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2045411817
- Cited by
- 97
- References
- 27
- Citations by year
- 2022: 1 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 5 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 4 · 2013: 8 · 2012: 2
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Atherosclerosis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- nicotinic acid, acipimox, lipoprotein(a), fractional catabolic rate, triglycerides, LDL cholesterol, HDL cholesterol, drug tolerability
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Cholesterol, Female, Humans, Hyperlipidemias, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Niacin, Pyrazines, Triglycerides, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. https://app.cochat.ai/papers/10.1016/0021-9150(93)90102-z
- The paper
- Seed, M., O'Connor, B., Perombelon, N., O'Donnell, M., Reaveley, D., & Knight, B. L. (1993). The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis. https://doi.org/10.1016/0021-9150(93)90102-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.